Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored
Background. Tacrolimus is the primary immunosuppressive drug used in kidney transplant patients. Replacing brand name products with generics is a controversial issue that we studied after a Chilean Ministry of Health mandate to implement such a switch. Methods. Forty-one stable Prograf (Astellas) re...
Saved in:
Main Authors: | Fernando González, René López, Elizabeth Arriagada, René Carrasco, Natalia Gallardo, Eduardo Lorca |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2017/5646858 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The association between serum tacrolimus concentrations and BK viruria in kidney transplant recipients
by: Napatsorn Kraivisitkul, et al.
Published: (2025-01-01) -
Evaluation of efficacy and safety of generic tacrolimus (Suprotac®) compared to reference tacrolimus (Prograf<sup>®</sup>) in kidney transplantation: a phase IV study
by: Behzad Einollahi, et al.
Published: (2025-01-01) -
Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient
by: Samuel Chan, et al.
Published: (2017-01-01) -
Immunization - Must Be Safe or We Will All Be Sorry
by: Greg Hammond
Published: (2001-01-01) -
Tacrolimus toxicity management in a pregnant kidney transplant recipient with newly diagnosed human immunodeficiency virus: A case report
by: Ahmad Matarneh, et al.
Published: (2025-02-01)